Wells Fargo Initiates Coverage On Atrium Therapeutics with Overweight Rating, Announces Price Target of $25
Benzinga Newsdesk 7 months ago
NewsPrice TargetInitiationAnalyst Ratings
Wells Fargo analyst Yanan Zhu initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Overweight rating and announces Price Target of $25.
Wells Fargo analyst Yanan Zhu initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Overweight rating and announces Price Target of $25.